
Eric S. Winer
Articles
-
Nov 26, 2024 |
newswise.com | Eric S. Winer |Tara Sanft
Yale Cancer Center (YCC) researchers at Yale School of Medicine will present new research at the 47th annual San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center from December 10 to 13. The international symposium will reveal new, leading-edge breast cancer research on prevention, etiology, diagnosis, and therapy as well as experimental biology.
-
Oct 2, 2024 |
newswise.com | Eric S. Winer
Dr. Eric Winer, director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital, can speak on the new American Cancer Society report revealing a three-decade decline in breast cancer mortality, but higher rates of breast cancer in younger women under the age of 50. It also revealed higher rates of breast cancer among Asian-Americans and Native Americans.
-
May 13, 2024 |
newswise.com | Eric S. Winer |Michael Cecchini |Roy S. Herbst |Barbara Burtness
Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. This year's meeting, themed “The Art and Science of Cancer Care: From Comfort to Cure” will include over 200 sessions.
-
May 1, 2024 |
newswise.com | Eric S. Winer
Connecticut Magazine released its “Top Doctors” issue today, listing some of the state’s best physicians, who provide exceptional care for patients. This year’s list includes 109 Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) physicians, a 35% increase in “Top Doctors” for SCH and YCC from last year. YCC is Connecticut’s only National Cancer Institute-designated comprehensive cancer center.
-
Feb 12, 2024 |
onlinelibrary.wiley.com | Yasmin Abaza |Eric S. Winer |Rory M. Shallis |Andrew Matthews |Talha Badar |Emily M. Geramita | +6 more
1 INTRODUCTION Acute myeloid leukemia (AML) is primarily a disease of the elderly with a median age at diagnosis of 69 years.1 Treatment of patients with AML ≥75 years of age, who are truly unfit for intensive chemotherapy, is challenging given the higher incidence of adverse risk disease, comorbidities, poor performance status, and compromised organ function.2-4 Although the outcomes of AML have significantly improved over the past 5 decades, the long-term survival remains poor with the...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →